
5.21.041

| | | | |
|--------------------|-----------------------|------------------------------|---------------|
| Section: | Prescription Drugs | Effective Date: | April 1, 2025 |
| Subsection: | Antineoplastic Agents | Original Policy Date: | March 7, 2014 |
| Subject: | Imbruvica | Page: | 1 of 7 |

Last Review Date: March 7, 2025

Imbruvica

Description

Imbruvica (ibrutinib)

Background

Imbruvica is a kinase inhibitor that is used to treat different types of cancer and chronic graft versus host disease. Imbruvica is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. Studies show that Imbruvica inhibits B-cell proliferation and survival (1).

Regulatory Status

FDA-approved indications: Imbruvica is a kinase inhibitor indicated for the treatment of patients with: (1)

1. Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL)
2. Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion
3. Adult patients with Waldenström's macroglobulinemia (WM)/lymphoplasmacytic lymphoma
4. Adult and pediatric patients 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy

Off-Label Uses: (2-4)

1. Follicular lymphoma (FL)
2. Diffuse large B-cell lymphoma (DLBCL)

| | | | |
|--------------------|-----------------------|------------------------------|---------------|
| Section: | Prescription Drugs | Effective Date: | April 1, 2025 |
| Subsection: | Antineoplastic Agents | Original Policy Date: | March 7, 2014 |
| Subject: | Imbruvica | Page: | 2 of 7 |

The B-cell antigen receptor (BCR) pathway is implicated in the pathogenesis of several B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle-cell lymphoma (MCL), and B-cell chronic lymphocytic leukemia (CLL). Bruton's tyrosine kinase (BTK) is a critical signaling kinase in this pathway. Imbruvica is an irreversible inhibitor of the BTK in patients with B-cell malignancies (2).

Patients treated with Imbruvica have a chance of Grade 3 or higher bleeding events (subdural hematoma, gastrointestinal bleeding, and hematuria). Imbruvica may increase the risk of hemorrhage in patients receiving antiplatelet or anticoagulant therapies. Consider the benefit-risk of withholding Imbruvica for at least 3 to 7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding (1).

Significant adverse reactions may occur with Imbruvica therapy including fatal and non-fatal infections, hemorrhage, cardiac arrhythmias and cardiac failure, hypertension, cytopenias, second primary malignancies, and tumor lysis syndrome. Patients should have the following monitored while on Imbruvica therapy: fever, infections, complete blood counts, creatinine levels, and hydration (1).

Advise women to avoid becoming pregnant while taking Imbruvica. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus (1).

The safety and effectiveness of Imbruvica in pediatric patients less than 1 years of age with cGVHD has not been established. The safety and effectiveness of Imbruvica in pediatric patients less than 18 years of age for all other indications has not been established (1).

Related policies

Aliqopa, Arzerra, Bendeka, Brukinsa, Calquence, Copiktra, Gazyva, Revlimid, Rituxan, Treanda, Zydelig

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Imbruvica may be considered **medically necessary** if the conditions indicated below are met.

Imbruvica may be considered **investigational** for all other indications.

| | | | |
|--------------------|-----------------------|------------------------------|---------------|
| Section: | Prescription Drugs | Effective Date: | April 1, 2025 |
| Subsection: | Antineoplastic Agents | Original Policy Date: | March 7, 2014 |
| Subject: | Imbruvica | Page: | 3 of 7 |

Prior-Approval Requirements

Age 18 years of age and older

Diagnoses

Patient must have **ONE** of the following:

1. Chronic lymphocytic leukemia (CLL)
2. Waldenström's macroglobulinemia (WM)/lymphoplasmacytic lymphoma
3. Follicular lymphoma (FL)
4. Diffuse large B-cell lymphoma (DLBCL)
5. Small lymphocytic lymphoma (SLL)

AND ALL of the following:

1. Prescriber agrees to monitor for bleeding and malignancies
 2. Prescriber agrees to monitor CBC for cytopenias
-

Age 1 year of age and older

Diagnosis

Patient must have the following:

1. Chronic graft versus host disease (cGVHD)
 - a. The patient has received at least one prior systemic therapy

AND ALL of the following:

1. Prescriber agrees to monitor for bleeding and malignancies
 2. Prescriber agrees to monitor CBC for cytopenias
-

Prior – Approval *Renewal* Requirements

Age 18 years of age and older

Diagnoses

| | | | |
|--------------------|-----------------------|------------------------------|---------------|
| Section: | Prescription Drugs | Effective Date: | April 1, 2025 |
| Subsection: | Antineoplastic Agents | Original Policy Date: | March 7, 2014 |
| Subject: | Imbruvica | Page: | 4 of 7 |

Patient must have **ONE** of the following:

1. Chronic lymphocytic leukemia (CLL)
2. Waldenström's macroglobulinemia (WM)/ lymphoplasmacytic lymphoma
3. Follicular lymphoma (FL)
4. Diffuse large B-cell lymphoma (DLBCL)
5. Small lymphocytic lymphoma (SLL)

AND ALL of the following:

1. **NO** disease progression or unacceptable toxicity
2. Prescriber agrees to monitor for bleeding and malignancies
3. Prescriber agrees to monitor CBC for cytopenias

Age 1 year of age and older

Diagnosis

Patient must have the following:

1. Chronic graft versus host disease (cGVHD)

AND ALL of the following:

1. **NO** disease progression or unacceptable toxicity
2. Prescriber agrees to monitor for bleeding and malignancies
3. Prescriber agrees to monitor CBC for cytopenias

Policy Guidelines

Pre - PA Allowance

None

Prior - Approval Limits

Quantity

| Strength | Daily Dosing Limits |
|----------|---------------------|
| 70 mg | 420 mg per day |
| 140 mg | |
| 140 mg | |
| 280 mg | |
| 420 mg | |

| | | | |
|--------------------|-----------------------|------------------------------|---------------|
| Section: | Prescription Drugs | Effective Date: | April 1, 2025 |
| Subsection: | Antineoplastic Agents | Original Policy Date: | March 7, 2014 |
| Subject: | Imbruvica | Page: | 5 of 7 |

| | |
|--------------------------|--|
| 70 mg/mL oral suspension | |
|--------------------------|--|

Duration 12 months

Prior – Approval *Renewal* Limits

Same as above

Rationale

Summary

Imbruvica is an orally administered kinase inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Waldenstrom's macroglobulinemia (WM), and chronic graft versus host disease (cGVHD). Warnings include infections, hemorrhage, cardiac arrhythmias and cardiac failure, hypertension, cytopenias, second primary malignancies, and tumor lysis syndrome. The safety and effectiveness of Imbruvica in pediatric patients less than 1 years of age with cGVHD has not been established. The safety and effectiveness of Imbruvica in pediatric patients less than 18 years of age for all other indications has not been established (1-4).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Imbruvica while maintaining optimal therapeutic outcomes.

References

1. Imbruvica [package insert]. Horsham, PA: Janssen Biotech, Inc; December 2024.
2. Advani, RH, Buggy JJ, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013 Jan 1; 31(1):88-94.
3. NCCN Drugs & Biologics Compendium[®] Ibrutinib 2025. National Comprehensive Cancer Network, Inc. Accessed on January 14, 2025.
4. NCCN Clinical Practice Guidelines in Oncology[®] B-Cell Lymphomas (Version 1.2025). National Comprehensive Cancer Network, Inc. December 2024. Accessed on January 14, 2025.

Policy History

| Date | Action |
|------------|--------------------|
| March 2014 | New addition to PA |

5.21.041

| | | | |
|--------------------|-----------------------|------------------------------|---------------|
| Section: | Prescription Drugs | Effective Date: | April 1, 2025 |
| Subsection: | Antineoplastic Agents | Original Policy Date: | March 7, 2014 |
| Subject: | Imbruvica | Page: | 6 of 7 |

| | |
|--------------------------------|--|
| September 2014 | Addition that the FDA indication of chronic lymphocytic leukemia (CLL) with 17p deletion does not require failure on prior therapy for CLL. Removal of the following criteria requirements: no baseline hepatic impairment, Physician agrees to monitor for: Hemorrhage, Myelosuppression with complete blood counts monthly, Renal toxicity by checking creatinine levels periodically, second primary malignancies including skin cancers. |
| December 2014 February 2015 | Annual editorial review and reference update Addition of Waldenström's macroglobulinemia, follicular lymphoma and diffuse large B-cell lymphoma |
| June 2015 March 2016 | Annual editorial review and reference update Addition of Small lymphocytic lymphoma (SLL) and removal of who have received at least one prior therapy or in patients with chronic lymphocytic leukemia with 17p deletion Policy number change from 5.04.41 to 5.21.41 |
| June 2016 | Annual review |
| September 2016 | Annual review |
| February 2017 | Addition of marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy |
| June 2017 | Annual editorial review Addition of age requirements to renewal criteria |
| August 2017 | Addition of chronic graft versus host disease (cGVHD) |
| September 2017 | Annual review |
| March 2018 | Annual editorial review Addition of quantity limits |
| March 2019 | Annual review and reference update |
| September 2019 | Addition of "maximum daily limit of any combination: 560 mg" |
| December 2019 | Annual review and reference update |
| March 2020 | Annual review and reference update. Removed systemic therapy requirement from MZL diagnosis for renewal. Added requirements to monitor for bleeding and malignancies and monitor CBC for cytopenias. Also added renewal requirement of no disease progression or unacceptable toxicity per SME |
| June 2021 | Annual review and reference update |
| December 2021 | Annual review and reference update |
| June 2022 | Annual review and reference update |
| September 2022 | Per PI update, revised age for cGVHD to 1 year and older from 18 and older. Added oral suspension to quantity chart and also revised chart to remove quantities and set all dosage forms and strengths at 560 mg per day |
| December 2022 | Annual review and reference update |
| March 2023 | Annual review and reference update |

5.21.041

| | | | |
|--------------------|-----------------------|------------------------------|---------------|
| Section: | Prescription Drugs | Effective Date: | April 1, 2025 |
| Subsection: | Antineoplastic Agents | Original Policy Date: | March 7, 2014 |
| Subject: | Imbruvica | Page: | 7 of 7 |

| | |
|------------|---|
| June 2023 | Annual editorial review and reference update. Per PI update, removed diagnoses of mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL). Also removed the 560 mg tablet from the quantity chart and decreased the limit to 420 mg per day |
| March 2024 | Annual review and reference update |
| March 2025 | Annual review and reference update |

[Keywords](#)

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 7, 2025 and is effective on April 1, 2025.